AVBP - NASDAQ

ArriVent BioPharma, Inc. Common Stock

AVBP·NASDAQ

$29.78

-0.47%

HealthcareBiotechnology

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.39B

EPS-4.3200

P/E Ratio-6.89

Earnings Date08/10/2026

avbp

Total Assets

Last Annual Value

333.17M

3-Year CAGR

22%

5-Year CAGR

51%

10-Year CAGR

23%

Adjust for Inflation

ArriVent BioPharma, Inc. Common Stock Competitors Analysis of Total Assets

AVBP · NASDAQ

Company	Total Assets	CAGR 3Y	CAGR 5Y	CAGR 10Y
ArriVent BioPharma, Inc. Common Stock NASDAQ:AVBP	333.17M	26.9%	50.6%	N/A
Erasca, Inc. NASDAQ:ERAS	396.15M	0.1%	-4.6%	N/A
MBX Biosciences, Inc. Common Stock NASDAQ:MBX	385.14M	66.0%	N/A	N/A
Replimune Group, Inc. NASDAQ:REPL	551.33M	-5.2%	0.3%	N/A
Arvinas, Inc. NASDAQ:ARVN	717.90M	-18.1%	-14.6%	34.2%
Ginkgo Bioworks Holdings, Inc. NYSE:DNA	1.12B	-12.4%	-11.6%	N/A
Iovance Biotherapeutics, Inc. NASDAQ:IOVA	913.17M	5.4%	3.3%	18.2%
MeiraGTx Holdings plc NASDAQ:MGTX	244.43M	-9.2%	-5.3%	26.9%
Astria Therapeutics, Inc. NASDAQ:ATXS	342.36M	10.4%	21.8%	23.9%
Day One Biopharmaceuticals, Inc. NASDAQ:DAWN	507.83M	10.5%	11.9%	N/A

ArriVent BioPharma, Inc. Common Stock Fair Value Envelope

AVBP · NASDAQ

Our analysis suggests that AVBP has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $29.78, this represents a potential HIDDEN relative to our calculated worth for ArriVent BioPharma, Inc. Common Stock.

HIDDEN

Intrinsic Value

Current Price: $29.78

Related Guides

Blog Categories

Continue your AVBP research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.